Brief: Medesis Pharma Says NanosiRNA HD Clinical Results Could Be Known Mid-2023
15/06/2021 18:04
June 15 (Reuters) - MEDESIS PHARMA SA ALMDP.PA :
* ON NANOSIRNA HD PROGRAMME: CLINICAL RESULTS COULD BE KNOWN
MID-2023
* ON NANOSIRNA COVID PROGRAMME: AN ANIMAL COVID MODEL IS
PLANNED
FOR THE MONTHS OF AUGUST/SEPTEMBER 2021
Source text: https://bit.ly/3gCvhGI
Further company coverage: ALMDP.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Medesis Pharma SA
See all newsBrief: Medesis Pharma FY EBIT Loss Widens To EUR 3.244 Mln
Brief: Medesis Pharma Signs A Partnership With Partner International
Brief: Medesis Pharma Issues Bond Financing With Maximum Potential Nominal Amount Of EUR 2.5 Mln
Brief: Medesis Pharma Creates Council For Neurodegenerative Diseases
Brief: Medesis Pharma H1 Operating Loss Widens To 1.8 Million Euros